Tdspharm Co., Ltd. (KOSDAQ:464280)
9,710.00
-410.00 (-4.05%)
At close: Dec 5, 2025
Tdspharm Revenue
Tdspharm had revenue of 8.08B KRW in the quarter ending September 30, 2025, with 25.01% growth. This brings the company's revenue in the last twelve months to 24.56B, down -20.27% year-over-year. In the year 2024, Tdspharm had annual revenue of 27.52B, down -8.42%.
Revenue (ttm)
24.56B
Revenue Growth
-20.27%
P/S Ratio
2.19
Revenue / Employee
n/a
Employees
n/a
Market Cap
53.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.52B | -2.53B | -8.42% |
| Dec 31, 2023 | 30.05B | 4.46B | 17.43% |
| Dec 31, 2022 | 25.59B | 5.77B | 29.11% |
| Dec 31, 2021 | 19.82B | 1.80B | 9.97% |
| Dec 31, 2020 | 18.02B | -1.19B | -6.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |